INDV Indivior Pharmaceuticals, Inc.

8-K Current Report

Filed: March 12, 2026

Health Care

Pharmaceutical Preparations

Indivior Pharmaceuticals, Inc. (INDV) 8-K current report filed with SEC EDGAR on March 12, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

• Indivior launching convertible senior notes due 2031, pricing expected imminently (March 12, 2026 announcement)
• Convertible notes create potential future equity dilution upon conversion into common stock

+1 more insights

Other Indivior Pharmaceuticals, Inc. 8-K Filings

8-K Mar 17, 2026

8-K Mar 13, 2026

8-K Feb 26, 2026

Get deeper insights on Indivior Pharmaceuticals, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.